UAB Researchers Discover why Brain Neurons in Parkinson's Disease Stop Benefiting from Levodopa
The mechanism may be therapeutic target to prevent or reverse dyskinesia
Though the drug levodopa (L-DOPA) can dramatically improve Parkinson’s disease symptoms, within five years one-half of the patients using L-DOPA develop an irreversible condition – involuntary repetitive, rapid and jerky movements. This abnormal motor behavior appears only while taking L-DOPA, a it stops if the drug is stopped. However, if L-DOPA is taken again, even many months later, it quickly re-emerges. In research to prevent this side effect and extend the usefulness of L-DOPA – which is the most effective drug treatment for Parkinson’s disease – University of Alabama at Birmingham researchers have uncovered an essential mechanism of this long-term memory for L-DOPA-induced-dyskinesia, or LID. To read more, click here.
GOODMAN Oral Board Preparation Course Tumor
Nov. 1-3, 2017; Glendale, Ariz.
2017 Managing Coding and Reimbursement Challenges
Aug. 17-19, 2017; Chicago
2017 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 30-Sept. 2, 2017; Chicago
Mayo Clinic Neuroscience and Oncology Innovation Summit 2017
Sept. 7-9, 2017; Orlando, Fla.
63rd Annual Meeting of the Western Neurological Society
Sept. 8-11, 2017; Banff, Alberta, Canada